Business Context and Reporting Period
Company: GlaxoSmithKline plc (GSK)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2013
Filing Date: February 28, 2014
Accounting Basis: International Financial Reporting Standards (IFRS)
GSK is a global pharmaceutical, vaccine, and consumer healthcare company. The 2013 reporting period was characterized by significant strategic restructuring, including the divestment of non-core Consumer Healthcare brands (Lucozade, Ribena, and anti-coagulant products) and the centralization of pharmaceutical intellectual property in the UK. The company operates in a highly regulated environment with exposure to patent expirations, generic competition, and government investigations.
Key Financial Metrics (2013)
| Metric | 2013 Total Results | 2013 Core Results | 2012 Total Results (Restated) |
|---|---|---|---|
| Turnover | £26,505 million | £25,602 million | £26,431 million |
| Operating Profit | £7,028 million | £7,771 million | £7,300 million |
| Profit Before Taxation | £6,647 million | £7,122 million | £6,600 million |
| Profit After Taxation | £5,628 million | £5,487 million | £4,678 million |
| Earnings Per Share (Total) | 112.5p | 108.4p (excl. divestments) | 91.6p |
| Net Debt | Increased by £5.0 billion in 2012; 2013 level not explicitly stated in summary tables | N/A | N/A |
| Operating Cash Flow | Filing text does not provide a clear 2013 value (2012 was £4,375 million) | N/A | £4,375 million |
Note: The filing provides detailed reconciliations between "Total Results" and "Core Results." Core results exclude intangible amortization, impairment, major restructuring, legal charges, and acquisition accounting adjustments.
Material Changes vs. Prior Period
- Profitability: Total profit after taxation increased significantly to £5,628 million in 2013 compared to £4,678 million in 2012. Core earnings per share (excluding divestments) was 108.4p, compared to 111.4p in 2012.
- Turnover: Total turnover remained relatively flat at £26,505 million in 2013 versus £26,431 million in 2012. However, core turnover excluding divestments was £25,602 million.
- Divestments: The company completed the disposal of non-core Consumer Healthcare brands (Lucozade, Ribena) and anti-coagulant products in 2013, contributing £903 million to turnover and £244 million to operating profit in the reconciliation tables.
- Legal and Restructuring: Significant non-core charges in 2013 included £739 million in intangible impairment and £517 million in major restructuring costs. Legal charges were £252 million.
- Segment Performance:
- Pharmaceuticals: Respiratory sales (led by Seretide/Advair) remained resilient, though facing generic pressure. Oncology and emesis showed strong growth.
- Vaccines: Performance improved in the latter half of the year, though Cervarix sales declined following the completion of the Japanese HPV catch-up program.
- Consumer Healthcare: Turnover was flat on a reported basis but grew 6% excluding divested brands, driven by strong growth in Rest of World markets.
Guidance, Outlook, and Risks
Outlook and Reporting Changes: GSK intends to report 2014 core results performance measured against 2013 core results excluding the divestments completed in 2013. The company aims to simplify its business structure through the centralization of pharmaceutical IP in the UK, which is expected to deliver supply chain and working capital efficiencies.
Key Risks and Contingencies:
- Patent Expirations: Significant exposure to generic competition, particularly for Seretide/Advair in the US (patent on device expires August 2016) and other major products.
- Legal and Regulatory: Ongoing exposure to product liability, antitrust, and sales/marketing litigation. The company resolved significant US federal government investigations in 2012, but state litigation and other disputes remain.
- Regulatory Compliance: Risks related to product quality, manufacturing compliance (GMP), and adverse event reporting.
- Taxation: Changes in tax laws and transfer pricing regulations could impact the effective tax rate. The company has entered into a bilateral Advance Pricing Agreement with the IRS and HMRC.
- Supply Chain: Risks of supply interruption due to reliance on single-source suppliers or regulatory non-compliance at manufacturing sites.
Investor Verification Checklist
- Divestment Impact: Verify the long-term impact of the Consumer Healthcare divestments on future revenue streams and the integration of remaining core brands.
- Patent Cliff: Assess the timeline and financial impact of generic entry for Seretide/Advair and other key pharmaceutical products in the US and Europe.
- Legal Provisions: Review Note 44 (Legal proceedings) in the full Annual Report to understand the adequacy of provisions for ongoing product liability and antitrust litigation.
- Core vs. Total Results: Analyze the reconciliation between core and total results to understand the magnitude of one-off charges (impairments, restructuring) affecting reported earnings.
- Tax Structure: Evaluate the implications of the centralization of IP in the UK and the new Advance Pricing Agreement on future effective tax rates.
- Debt Levels: Confirm the current net debt position, as the filing notes a £5.0 billion increase in 2012 due to legal settlements and acquisitions, with 2013 specific debt figures requiring review of the full balance sheet.